Oncolytics Biotech Files 6-K

Ticker: ONCY · Form: 6-K · Filed: May 15, 2024 · CIK: 1129928

Oncolytics Biotech INC 6-K Filing Summary
FieldDetail
CompanyOncolytics Biotech INC (ONCY)
Form Type6-K
Filed DateMay 15, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: reporting, foreign-private-issuer, sec-filing

Related Tickers: ONCY

TL;DR

ONCOLYTICS BIOTECH INC (ONCY) filed a 6-K, standard foreign issuer report.

AI Summary

Oncolytics Biotech Inc. filed a Form 6-K on May 15, 2024, reporting as a foreign private issuer. The company, based in Calgary, Alberta, Canada, is in the Pharmaceutical Preparations industry and uses the standard industrial classification code 2834. This filing is made pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.

Why It Matters

This filing indicates Oncolytics Biotech Inc. is complying with SEC reporting requirements as a foreign private issuer, which is standard for international companies trading on US exchanges.

Risk Assessment

Risk Level: low — This is a routine administrative filing for a foreign private issuer and does not contain new material financial or operational information.

Key Players & Entities

FAQ

What type of filing is this Form 6-K?

This Form 6-K is a Report of Foreign Private Issuer.

What is the company's name and location?

The company's name is Oncolytics Biotech Inc., and its principal executive offices are located in Calgary, Alberta, Canada.

What is the Commission File Number for Oncolytics Biotech Inc.?

The Commission File Number for Oncolytics Biotech Inc. is 001-38512.

What is the Standard Industrial Classification code for Oncolytics Biotech Inc.?

The Standard Industrial Classification code for Oncolytics Biotech Inc. is 2834, which corresponds to Pharmaceutical Preparations.

What is the reporting period for this Form 6-K?

The reporting period for this Form 6-K is the month of May 2024.

Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17 · Accepted 2024-05-15 07:06:37

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date May 15, 2024 Kirk Look Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing